DERMAGNOSTIX
Financiado
Pioneering diagnostics in dermatology and cancer
At Dermagnostix, we envision the next level for molecular diagnostics in human skin to improve patients’ lives and clinical practice in dermatology.
Skin diseases are the 4th most relevant human illnesses according to loss of qual...
At Dermagnostix, we envision the next level for molecular diagnostics in human skin to improve patients’ lives and clinical practice in dermatology.
Skin diseases are the 4th most relevant human illnesses according to loss of quality of life. Conventional diagnostics in dermatology based on clinical view and histopathology are imprecise and subjective, resulting in up to 50% of misdiagnosed cases and insufficient or harmful therapies.
At Dermagnostix, we have developed a comprehensive technological platform for fast and objective molecular diagnostics in dermatology to reduce health care costs and improve patient treatment. Our fully automated platform delivers results within 90 min and testing can be run everywhere and at any time. Our easy-to-handle diagnostic device brings objective and precise skin diagnostics to reality allowing simultaneous detection of up to 40 different molecular targets within one single test.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2022-09-23
Fecha Fin: 2024-09-30
Fecha Fin: 2024-09-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2022-ACCELERATOROPEN-01:
EIC Accelerator Open
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
5M€
Líder del proyecto
DERMAGNOSTIX GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
